{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T03:57:34Z","timestamp":1790827054894,"version":"4.1.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,30]],"date-time":"2021-12-30T00:00:00Z","timestamp":1640822400000},"content-version":"vor","delay-in-days":363,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004901","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de Minas Gerais","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004901","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient&#x00ED;fico e Tecnol&#x00F3;gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.vaccine.2020.11.064","type":"journal-article","created":{"date-parts":[[2020,12,11]],"date-time":"2020-12-11T10:58:41Z","timestamp":1607684321000},"page":"282-291","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Lipophosphoglycan-3 protein from Leishmania infantum chagasi plus saponin adjuvant: A new promising vaccine against visceral leishmaniasis"],"prefix":"10.1016","volume":"39","author":[{"given":"Sabrina","family":"de Oliveira Emerick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tha\u00eds","family":"Vieira de Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Meirelles Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Carneiro da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tha\u00eds","family":"Viana Fialho Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandro","family":"Licursi de Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"de Almeida Marques-da-Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.11.064_b0005","unstructured":"WHO\/Expert Committee on the Control of Leishmaniases. Control of the leishmaniases: WHO TRS N\u00b0949 - report of a meeting of the WHO Expert Committee on the Control of Leishmaniases, Geneva, 22\u201326 March 2010. In: WHO, editor.2010."},{"key":"10.1016\/j.vaccine.2020.11.064_b0010","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.pt.2017.02.002","article-title":"The expanding world of human leishmaniasis","volume":"33","author":"Cotton","year":"2017","journal-title":"Trends Parasitol"},{"key":"10.1016\/j.vaccine.2020.11.064_b0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0035671","article-title":"Leishmaniasis worldwide and global estimates of its incidence","volume":"7","author":"Alvar","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2020.11.064_b0020","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.pt.2006.06.012","article-title":"Phlebotomine sand flies and Leishmania parasites: friends or foes?","volume":"22","author":"Kamhawi","year":"2006","journal-title":"Trends Parasitol"},{"key":"10.1016\/j.vaccine.2020.11.064_b0025","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1590\/S0074-02762005000800001","article-title":"Lutzomyia longipalpis and the eco-epidemiology of American visceral leishmaniasis, with particular reference to Brazil: a review","volume":"100","author":"Lainson","year":"2005","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"10.1016\/j.vaccine.2020.11.064_b0030","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1756-3305-4-86","article-title":"LeishVet guidelines for the practical management of canine leishmaniosis","volume":"4","author":"Solano-Gallego","year":"2011","journal-title":"Parasit Vectors"},{"key":"10.1016\/j.vaccine.2020.11.064_b0035","article-title":"Canine-based strategies for prevention and control of visceral leishmaniasis in Brazil","volume":"11","author":"Seva","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2020.11.064_b0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0110014","article-title":"Mimotope-based vaccines of Leishmania infantum antigens and their protective efficacy against visceral leishmaniasis","volume":"9","author":"Costa","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2020.11.064_b0045","doi-asserted-by":"crossref","first-page":"440","DOI":"10.3201\/eid1203.050811","article-title":"Canine visceral leishmaniasis, United States and Canada, 2000\u20132003","volume":"12","author":"Duprey","year":"2006","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2020.11.064_b0050","doi-asserted-by":"crossref","first-page":"122","DOI":"10.4269\/ajtmh.17-0490","article-title":"Case report: First coinfection report of mixed Leishmania infantum\/Leishmania major and human immunodeficiency virus-acquired immune deficiency syndrome: report of a case of disseminated cutaneous leishmaniasis in Iran","volume":"98","author":"Badirzadeh","year":"2018","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2020.11.064_b0055","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s00430-015-0422-1","article-title":"The genetics of Leishmania virulence","volume":"204","author":"Bifeld","year":"2015","journal-title":"Med Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2020.11.064_b0060","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.parint.2014.04.002","article-title":"A comparative evaluation of efficacy of chemotherapy, immunotherapy and immunochemotherapy in visceral leishmaniasis-an experimental study","volume":"63","author":"Joshi","year":"2014","journal-title":"Parasitol Int"},{"key":"10.1016\/j.vaccine.2020.11.064_b0065","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.idc.2018.10.005","article-title":"Visceral leishmaniasis: recent advances in diagnostics and treatment regimens","volume":"33","author":"van Griensven","year":"2019","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.vaccine.2020.11.064_b0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006123","article-title":"Human Neutrophil Peptide 1 as immunotherapeutic agent against Leishmania infected BALB\/c mice","volume":"11","author":"Abdossamadi","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2020.11.064_b0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005706","article-title":"Efficacy and safety of available treatments for visceral leishmaniasis in Brazil: A multicenter, randomized, open label trial","volume":"11","author":"Romero","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2020.11.064_b0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2015.03.017","article-title":"Vaccines for visceral leishmaniasis: a review","volume":"422","author":"Jain","year":"2015","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.vaccine.2020.11.064_b0085","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1590\/0037-8682-0022-2012","article-title":"Involvement and interactions of different immune cells and their cytokines in human visceral leishmaniasis","volume":"46","author":"Bhattacharya","year":"2013","journal-title":"Rev Soc Bras Med Trop"},{"key":"10.1016\/j.vaccine.2020.11.064_b0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002914","article-title":"Immune regulation during chronic visceral leishmaniasis","volume":"8","author":"Faleiro","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2020.11.064_b0095","doi-asserted-by":"crossref","DOI":"10.1111\/pim.12605","article-title":"Sambucus ebulus extract stimulates cellular responses in cutaneous leishmaniasis","volume":"41","author":"Heidari-Kharaji","year":"2019","journal-title":"Parasite Immunol"},{"key":"10.1016\/j.vaccine.2020.11.064_b0100","first-page":"1","article-title":"Arginase\/nitric oxide modifications using live non-pathogenic Leishmania tarentolae as an effective delivery system inside the mammalian macrophages","author":"Badirzadeh","year":"2020","journal-title":"J Parasitic Diseases"},{"key":"10.1016\/j.vaccine.2020.11.064_b0105","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cellimm.2016.07.004","article-title":"Role of pro-inflammatory cytokine IL-17 in Leishmania pathogenesis and in protective immunity by Leishmania vaccines","volume":"309","author":"Banerjee","year":"2016","journal-title":"Cell Immunol"},{"key":"10.1016\/j.vaccine.2020.11.064_b0110","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1093\/infdis\/jiu531","article-title":"Interleukin 17A acts synergistically with interferon gamma to promote protection against Leishmania infantum infection","volume":"211","author":"Nascimento","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.11.064_b0115","first-page":"2379","article-title":"IL-17 and IL-22 are associated with protection against human kala azar caused by Leishmania donovani","volume":"119","author":"Pitta","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2020.11.064_b0120","doi-asserted-by":"crossref","first-page":"670","DOI":"10.3389\/fimmu.2019.00670","article-title":"Cytokines: key determinants of resistance or disease progression in visceral leishmaniasis: opportunities for novel diagnostics and immunotherapy","volume":"10","author":"Dayakar","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2020.11.064_b0125","doi-asserted-by":"crossref","first-page":"95","DOI":"10.4103\/ijpvm.IJPVM_116_18","article-title":"Leishmania vaccines entered in clinical trials: a review of literature","volume":"10","author":"Moafi","year":"2019","journal-title":"Int J Prev Med"},{"key":"10.1016\/j.vaccine.2020.11.064_b0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0185438","article-title":"Field trial of efficacy of the Leish-tec(R) vaccine against canine leishmaniasis caused by Leishmania infantum in an endemic area with high transmission rates","volume":"12","author":"Grimaldi","year":"2017","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2020.11.064_b0135","doi-asserted-by":"crossref","first-page":"5888","DOI":"10.1016\/j.vaccine.2008.05.095","article-title":"Protective immunity against challenge with Leishmania (Leishmania) chagasi in beagle dogs vaccinated with recombinant A2 protein","volume":"26","author":"Fernandes","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.11.064_b0140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001683","article-title":"Use of a LiESP\/QA-21 vaccine (CaniLeish) stimulates an appropriate Th1-dominated cell-mediated immune response in dogs","volume":"6","author":"Moreno","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2020.11.064_b0145","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1297-9716-45-69","article-title":"The protective immune response produced in dogs after primary vaccination with the LiESP\/QA-21 vaccine (CaniLeish(R)) remains effective against an experimental challenge one year later","volume":"45","author":"Martin","year":"2014","journal-title":"Vet Res"},{"key":"10.1016\/j.vaccine.2020.11.064_b0150","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3389\/fimmu.2015.00524","article-title":"Kinetoplastid membrane protein-11 as a vaccine candidate and a virulence factor in Leishmania","volume":"6","author":"de Mendonca","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2020.11.064_b0155","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1365-3024.2010.01253.x","article-title":"Cocktail of gp63 and Hsp70 induces protection against Leishmania donovani in BALB\/c mice","volume":"33","author":"Kaur","year":"2011","journal-title":"Parasite Immunol"},{"key":"10.1016\/j.vaccine.2020.11.064_b0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003490","article-title":"Vaccination with Leishmania infantum acidic ribosomal P0 but not with nucleosomal histones proteins controls Leishmania infantum infection in hamsters","volume":"9","author":"Pereira","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2020.11.064_b0165","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0966-842X(97)01180-3","article-title":"Lipophosphoglycan (LPG) and the identification of virulence genes in the protozoan parasite Leishmania","volume":"6","author":"Beverley","year":"1998","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.vaccine.2020.11.064_b0170","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/j.biopha.2017.09.061","article-title":"New insights to structure and immunological features of Leishmania lipophosphoglycan3","volume":"95","author":"Hosseini","year":"2017","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.vaccine.2020.11.064_b0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1177932218763363","article-title":"Lipophosphoglycan 3 from Leishmania infantum chagasi binds heparin with micromolar affinity","volume":"12","author":"Martins","year":"2018","journal-title":"Bioinform Biol Insights"},{"key":"10.1016\/j.vaccine.2020.11.064_b0180","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.molbiopara.2015.12.005","article-title":"Leishmania chagasi heparin-binding protein: Cell localization and participation in L. chagasi infection","volume":"204","author":"Martins","year":"2015","journal-title":"Mol Biochem Parasitol"},{"key":"10.1016\/j.vaccine.2020.11.064_b0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110097","article-title":"Lipophosphoglycan-3 recombinant protein vaccine controls hepatic parasitism and prevents tissue damage in mice infected by Leishmania infantum chagasi","volume":"126","author":"Bastos","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.vaccine.2020.11.064_b0190","doi-asserted-by":"crossref","DOI":"10.1111\/pim.12461","article-title":"Leishmania tarentolae expressing CXCL-10 as an efficient immunotherapy approach against Leishmania major-infected BALB\/c mice","volume":"39","author":"Montakhab-Yeganeh","year":"2017","journal-title":"Parasite Immunol"},{"key":"10.1016\/j.vaccine.2020.11.064_b0195","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0021-9258(19)52451-6","article-title":"Protein measurement with the Folin phenol reagent","volume":"193","author":"Lowry","year":"1951","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2020.11.064_b0200","doi-asserted-by":"crossref","unstructured":"Donovan J, Brown P. Euthanasia. Curr Protoc Neurosci 2005;Appendix 4:Appendix 4H.","DOI":"10.1002\/0471142301.nsa04hs33"},{"key":"10.1016\/j.vaccine.2020.11.064_b0205","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1365-3024.1985.tb00098.x","article-title":"A limiting dilution assay for quantifying Leishmania major in tissues of infected mice","volume":"7","author":"Titus","year":"1985","journal-title":"Parasite Immunol"},{"key":"10.1016\/j.vaccine.2020.11.064_b0210","doi-asserted-by":"crossref","unstructured":"Marques-da-Silva dA, de Oliveira JC, Figueiredo AB, de Souza Lima JD, Carneiro CM, Rangel Fietto JL, et al. Extracellular nucleotide metabolism in Leishmania: influence of adenosine in the establishment of infection. Microbes Infect 2008;10:850-7.","DOI":"10.1016\/j.micinf.2008.04.016"},{"key":"10.1016\/j.vaccine.2020.11.064_b0215","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1016\/j.vaccine.2019.04.092","article-title":"Visceral leishmaniasis: an overview of vaccine adjuvants and their applications","volume":"37","author":"Ratnapriya","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.11.064_b0220","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1080\/08820139.2016.1208217","article-title":"T Helper 1 (Th1), Th2, and Th17 Responses to Leishmania major Lipophosphoglycan 3","volume":"45","author":"Miahipour","year":"2016","journal-title":"Immunol Invest"},{"key":"10.1016\/j.vaccine.2020.11.064_b0225","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/sji.12557","article-title":"A Non-pathogenic Recombinant Leishmania Expressing Lipophosphoglycan 3 Against Experimental Infection with Leishmania infantum","volume":"86","author":"Pirdel","year":"2017","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.vaccine.2020.11.064_b0230","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/pim.12147","article-title":"Immune response in susceptible BALB\/c mice immunized with DNA encoding Lipophosphoglycan 3 of Leishmania infantum","volume":"36","author":"Pirdel","year":"2014","journal-title":"Parasite Immunol"},{"key":"10.1016\/j.vaccine.2020.11.064_b0235","doi-asserted-by":"crossref","DOI":"10.1111\/pim.12345","article-title":"Immune response to recombinant Leishmania infantum lipophosphoglycan 3 plus CpG oligodeoxynucleotides in BALB\/c mice","volume":"39","author":"Pirdel","year":"2017","journal-title":"Parasite Immunol"},{"key":"10.1016\/j.vaccine.2020.11.064_b0240","first-page":"554","article-title":"Recombinant LPG3 stimulates IFN-gamma and TNF-A secretion by human NK cells","volume":"10","author":"Rasolzadeh","year":"2015","journal-title":"Iran J Parasitol"},{"key":"10.1016\/j.vaccine.2020.11.064_b0245","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.4049\/jimmunol.175.4.2517","article-title":"IL-10 from regulatory T cells determines vaccine efficacy in murine Leishmania major infection","volume":"175","author":"Stober","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2020.11.064_b0250","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001874","article-title":"Cytokine responses to novel antigens in an Indian population living in an area endemic for visceral leishmaniasis","volume":"6","author":"Singh","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2020.11.064_b0255","first-page":"30","article-title":"Prophylactic interferon-gamma and interleukin-17 facilitate parasite clearance in experimental visceral leishmaniasis","volume":"9","author":"Kumar","year":"2019","journal-title":"Trop Parasitol"},{"key":"10.1016\/j.vaccine.2020.11.064_b0260","doi-asserted-by":"crossref","first-page":"7269","DOI":"10.1016\/j.vaccine.2019.09.067","article-title":"Effect on cellular recruitment and the innate immune response by combining saponin, monophosphoryl lipid-A and Incomplete Freund's Adjuvant with Leishmania (Viannia) braziliensis antigens for a vaccine formulation","volume":"37","author":"Vitoriano-Souza","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.11.064_b0265","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1172\/JCI116570","article-title":"Interleukin 10 production correlates with pathology in human Leishmania donovani infections","volume":"92","author":"Ghalib","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2020.11.064_b0270","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.vetpar.2018.03.010","article-title":"Therapeutic vaccine of killed Leishmania amazonensis plus saponin reduced parasite burden in dogs naturally infected with Leishmania infantum","volume":"254","author":"Viana","year":"2018","journal-title":"Vet Parasitol"},{"key":"10.1016\/j.vaccine.2020.11.064_b0275","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003213","article-title":"A randomised, double-blind, controlled efficacy trial of the LiESP\/QA-21 vaccine in naive dogs exposed to two Leishmania infantum transmission seasons","volume":"8","author":"Oliva","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2020.11.064_b0280","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.exppara.2015.03.027","article-title":"Evaluation of adjuvant activity of fractions derived from Agaricus blazei, when in association with the recombinant LiHyp1 protein, to protect against visceral leishmaniasis","volume":"153","author":"de Jesus Pereira","year":"2015","journal-title":"Exp Parasitol"},{"key":"10.1016\/j.vaccine.2020.11.064_b0285","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1016\/j.vaccine.2008.07.029","article-title":"Immunogenicity assay of the Leishmune vaccine against canine visceral leishmaniasis in Brazil","volume":"26","author":"Borja-Cabrera","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.11.064_b0290","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1016\/j.vaccine.2016.03.019","article-title":"Field randomized trial to evaluate the efficacy of the Leish-Tec(R) vaccine against canine visceral leishmaniasis in an endemic area of Brazil","volume":"34","author":"Regina-Silva","year":"2016","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20315395?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20315395?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:50:16Z","timestamp":1759402216000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20315395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":58,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S0264410X20315395"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.11.064","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipophosphoglycan-3 protein from Leishmania infantum chagasi plus saponin adjuvant: A new promising vaccine against visceral leishmaniasis","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.11.064","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}